Thomas Weisel Ups Harvard Bioscience to 'Outperform'

Analyst Paul Knight says the upgrade is based on strong second-quarter operating performance and a string of successful acquisitions

Thomas Weisel upgraded Harvard Bioscience (HBIO ) to outperform from peer perform.

Analyst Paul Knight says the upgrade is based on: Strong second-quarter operating performance, vs. previous periods; a string of successful acquisition consolidations (Genomic Solutions, Gene Machines, and BioRobotics) that are expanding margins; and, potential growth benefit from improved pharmaceutical demand.

Knight notes second-quarter results marked the best performance in more than a year. He thinks Harvard Bioscience's position in the pharmceutical industry (65% exposure) leverages its business model to benefit from a spending up cycle that's driven by the conclusion of the Pfizer/Pharmacia consolidation. Knight sees 25 cents 2003 earnings per share, 30 cents per share for 2004, and 40 cents per share for 2005.

Before it's here, it's on the Bloomberg Terminal.